Literature DB >> 27649267

Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain.

Andrew A Somogyi1, Alex T Sia, Ene-Choo Tan, Janet K Coller, Mark R Hutchinson, Daniel T Barratt.   

Abstract

Although several genetic factors have been associated with postsurgical morphine requirements, those involving the innate immune system and cytokines have not been well investigated. The aim of this study was to investigate the contribution of genetic variability in innate immune signalling pathways to variability in morphine dosage after elective caesarean section under spinal anaesthesia in 133 Indian, 230 Malay, and 598 Han Chinese women previously studied. Twenty single nucleotide polymorphisms in 14 genes involved in glial activation (TLR2, TLR4, MYD88, MD2), inflammatory signalling (IL2, IL6, IL10, IL1B, IL6R, TNFA, TGFB1, CRP, CASP1), and neuronal regulation (BDNF) were newly investigated, in addition to OPRM1, COMT, and ABCB1 genetic variability identified previously. Postsurgical patient-controlled analgesia morphine use (mg/24 hours) was binned into 6 normally distributed groups and scored 0 to 5 to facilitate step-down multiple linear regression analysis of genetic predictors, controlling for ethnicity and nongenetic variables. Ethnicity, OPRM1 rs1799971 (increased), TLR2 rs3804100 (decreased), and an interaction between ethnicity and IL1B rs1143634 (increased), predicted 9.8% of variability in morphine use scores in the entire cohort. In the Indian cohort, 14.5% of the variance in morphine use score was explained by IL1B rs1143634 (increased) and TGFB1 rs1800469 (decreased). In Chinese patients, the incidence of postsurgical pain was significantly higher in variant COMT rs4680 genotypes (P = 0.0007) but not in the Malay or Indian cohorts. Innate immune genetics may contribute to variability in postsurgical opioid requirements in an ethnicity-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27649267     DOI: 10.1097/j.pain.0000000000000661

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

1.  Innate immune activation and depressive and anxious symptoms across the peripartum: An exploratory study.

Authors:  Lauren M Osborne; Gayane Yenokyan; Kezhen Fei; Thomas Kraus; Thomas Moran; Catherine Monk; Rhoda Sperling
Journal:  Psychoneuroendocrinology       Date:  2018-08-31       Impact factor: 4.905

Review 2.  Employing pain and mindfulness to understand consciousness: a symbiotic relationship.

Authors:  Joshua A Grant; Fadel Zeidan
Journal:  Curr Opin Psychol       Date:  2019-01-09

3.  Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits.

Authors:  Jin Li; Zhi Wei; Jie Zhang; Hakon Hakonarson; Scott D Cook-Sather
Journal:  Pharmacogenomics J       Date:  2019-02-14       Impact factor: 3.550

4.  Single nucleotide polymorphisms associated with postoperative inadequate analgesia after single-port VATS in Chinese population.

Authors:  Xiufang Xing; Yongyu Bai; Kai Sun; Min Yan
Journal:  BMC Anesthesiol       Date:  2020-02-05       Impact factor: 2.217

5.  Computational Functional Genomics-Based AmpliSeq™ Panel for Next-Generation Sequencing of Key Genes of Pain.

Authors:  Dario Kringel; Sebastian Malkusch; Eija Kalso; Jörn Lötsch
Journal:  Int J Mol Sci       Date:  2021-01-16       Impact factor: 5.923

6.  Development of an AmpliSeqTM Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain.

Authors:  Dario Kringel; Mari A Kaunisto; Catharina Lippmann; Eija Kalso; Jörn Lötsch
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

7.  No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation.

Authors:  Rong Hu; Daniel T Barratt; Janet K Coller; Benedetta C Sallustio; Andrew A Somogyi
Journal:  Front Pharmacol       Date:  2020-02-20       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.